Survival Prolongation by Rationale Innovative Genomics

During the Phase 1 (approximately 30 patients), the tri-therapy will be tested at different
doses following a specific dose-escalation scheme (3 + 3 model) in order to establish the
safety and identify the Maximum Tolerated Dose (MTD) and recommended dose (RP2D) for the
Phase 2. The phase 2 will confirm the safety and will assess the clinical utility of the
tri-therapy approach in the treatment of advanced/metastatic NSCLC (100 patients). The study
will also explore the clinical utility of the Simplified Interventional Mapping System
(SIMS), a new tool/algorithm enabling matching of NSCLC patients with combination therapy.
For this purpose tumor/metastasis and matched normal tissue biopsies will be requested in
order to obtain sequencing and expression profiles.

INCLUSION CRITERIA:

1. Age: Men and women aged ≥ 18 years,

2. Signed written informed consent,

3. Any histologic type of locally advanced or metastatic NSCLC,

4. Life expectancy of ≥ 12 weeks,

5. Measurable or evaluable (cytologically or radiologically detectable disease such as
ascites, peritoneal deposits, or lesions which do not fulfill RECIST 1.1 criteria for
measurable disease) lesions according to RECIST v1.1 criteria for phase 1 portion. For
phase 2, all patients must have RECIST 1.1 measurable disease,

6. Physiologic function:

- Hematologic function: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet
count ≥ 100 × 109/L, and hemoglobin ≥ 9 g/dL (may have been transfused),

- Hepatic function: Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN)
range and aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
levels ≤ 2.5 × ULN,

- Renal function: Estimated creatinine clearance ≥ 30 mL/min according to the
Cockcroft-Gault formula (or local institutional standard method).

7. Pregnancy and contraception:

- Pregnancy test: Negative serum or urine pregnancy test at screening for women of
childbearing potential,

- Contraception: Highly effective contraception for both male and female subjects
throughout the study and for 90 days after last avelumab treatment administration
if the risk of conception exists.

8. Ability to comply with protocol requirements,

9. Willingness to consent and ability to undergo a trucut biopsy to obtain a fresh
metastasis or primary tumor biopsy in case no adequate tumoral tissue is available,
and to undergo fibroscopy to obtain a biopsy from normal bronchial mucosa,

10. No serious or medically uncontrolled concomitant conditions that are likely to make
the patient unfit for SPRING combination therapy, as per investigator assessment,

11. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

EXCLUSION CRITERIA:

1. Patients with documented oncogenic aberrations at enrollment: EGFR, ALK, ROS1 when
available, MET exon 14 skipping when available.

Note: For Phase 1 portion, all patients with adenocarcinoma histology must have
documentation of results for druggable oncogenic aberrations (EGFR mutations, ALK
rearrangements, and ROS1 when available) prior to enrollment on the study.

2. For Phase 1 portion, >2 lines of prior therapy in the metastatic setting.

3. For the dose escalation phase of the study or until the MTD for the combination
regimen has been determined, patients with moderate hepatic impairment defined as AST,
ALT, alkaline phosphatase (ALP) >5 times ULN, which would be grade 3 or higher.
However patients with liver metastases with AST/ALT ≤ 5 x ULN can be included in the
study.

4. For Phase 2 portion, any prior therapy in the metastatic setting.

Clinical exclusion criteria for Phase 1 and Phase 2 studies:

1. Documented untreated central nervous system metastases (indicated by clinical
symptoms, cerebral edema, steroid requirement, or progressive disease in the prior
four weeks),

2. Participants with a history of myocardial infarction within the last 2 years or with
significant cardiac arrhythmias uncontrolled by medication or pacemaker,

3. Participants with any history of interstitial lung disease,

4. Prior clinically significant toxicities from anticancer agents or radiotherapy which
have not regressed to Grade ≤ 1 severity (NCI-CTCAE version 4.03) apart from
peripheral neuropathy and alopecia,

5. History of any second malignancy in the last two years; patients with prior history of
in-situ cancer or basal or squamous cell skin cancer are eligible. Patients with a
history of other malignancies are eligible if they have been continuously disease-free
for at least two years,

6. Autoimmune condition requiring medical intervention,

7. Uncontrolled concomitant illness, active infection requiring i.v. antibiotics,

8. Participants who are at risk for, or who have a history of arterial thromboembolic
events within the past 12 months and/or venous thromboembolic events within the past 6
months, or have had any recent active gastrointestinal bleeding,

9. Prior > G3 hemoptysis, major blood vessel involvement, and/or central cavitations,

10. Known or suspected drug hypersensitivity to any drug used in the combination,

11. Difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or
conditions that may hamper compliance and/or absorption of the oral drugs,

12. Any condition (e.g., known or suspected poor compliance, psychological instability,
geographical location, etc.) that, in the judgment of the investigator may affect the
patient's ability to sign the informed consent and undergo study procedures,

13. Taking another experimental drugs within 28 days prior to day 1 of the protocol
medications in this study,

14. Pregnant or breast-feeding women,

15. Both male and female patients of reproductive potential must agree to use a reliable
method of birth control, during the study and for 3 months following the last dose of
study drug,

16. Patients currently taking strong CYP3A4 inducers and inhibitors.

17. Patients currently taking proton pump inhibitors due to their impact on the
disposition of palbociclib during the dose escalation phase,

18. Other anticancer agents and anticoagulants are excluded (except for low doses of
anticoagulants used for access lines)

19. A time period of at least three weeks or five drug half-lives, whichever is shorter
must have elapsed from last non-investigational therapy before day 1 of treatment on
this study,

20. Specific exclusion criteria for administration of avelumab, in combination:

- IMMUNOSUPRESSANTS: Current use of immunosuppressive medication, EXCEPT for the
following: a. intranasal, inhaled, topical steroids, or local steroid injection
(e.g., intra-articular injection); b. Systemic corticosteroids at physiologic
doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for
hypersensitivity reactions (e.g., CT scan premedication).

- AUTOIMMUNE DISEASE: Active autoimmune disease that might deteriorate when
receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo,
psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive
treatment are eligible.

- ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell
transplantation.

- INFECTIONS: Active infection requiring systemic therapy.

- HIV/AIDS: Known history of testing positive for HIV or known acquired
immunodeficiency syndrome.

- HEPATITIS: Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at
screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening
test positive).

- VACCINATION: Vaccination within 4 weeks of the first dose of avelumab and while
on trials is prohibited except for administration of inactivated vaccines.

- HYPERSENSITIVITY TO STUDY DRUG: Known prior severe hypersensitivity to
investigational product or any component in its formulations, including known
severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade
≥ 3).

- CARDIOVASCULAR DISEASE: Clinically significant (i.e., active) cardiovascular
disease: cerebral vascular accident/stroke (< 6 months prior to enrollment),
myocardial infarction (< 6 months prior to enrollment), unstable angina,
congestive heart failure (≥ New York Heart Association Classification Class II),
or serious cardiac arrhythmia requiring medication.

- OTHER PERSISTING TOXICITIES: Persisting toxicity related to prior therapy (NCI
CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or
other Grade ≤ 2 not constituting a safety risk based on investigator's judgment
are acceptable.

- Other severe acute or chronic medical conditions including colitis, inflammatory
bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions
including recent (within the past year) or active suicidal ideation or behavior;
or laboratory abnormalities that may increase the risk associated with study
participation or study treatment administration or may interfere with the
interpretation of study results and, in the judgment of the investigator, would
make the patient inappropriate for entry into this study.